Envafolimab Plus Docetaxel In Combination With or Without Trilaciclib Versus Docetaxel in Advanced NSCLC
Status:
Not yet recruiting
Trial end date:
2026-06-30
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of Envafolimab Plus Docetaxel in combination with or
without Trilaciclib versus docetaxel IN patients with advanced non-small cell lung cancer
previously treated with a PD-1 inhibitor combined with chemotherapy